West Pharmaceutical Services, I (WST) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $2.66
- Estimate
- $2.20
- Surprise
- +21.1%
- Revenue (period 2026-09-30)
- $874.5M
- Score at report (before → after)
- 6.2 → 6.2/10
Revenue source: xbrl.
How the report landed
West Pharmaceutical Services, I (WST) beat the $2.20 estimate with adjusted EPS of $2.66 — a large 21.1% upside surprise. TrendMatrix's engine moved from Buy (Wait) (6.2/10) to Hold at 6.2/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates WST Hold at 6.3/10.
4 of the last 4 quarters beat the estimate; this quarter's +21.1% surprise compares with a +18.4% four-quarter average.
What supports the rating
- V7 quality resilience bonus: +0.2 (Q=7.3 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Supplier: single-source raw materials
- Concentration risk — Geographic: international sales (56.7%)
- Analyst target reached - limited upside remaining
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $416.67
- Stop
- $397.23
The stock trades at 53.4× trailing but 41.7× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 96 — a level conventionally read as overbought; gains at these levels often lean on momentum; trading volume is running 3.1× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-10-30 — shown for context, not personalized investment advice.
WST at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Instruments & Supplies
- Market cap
- $29.32B
- P/E (fwd)
- 41.7
- P/E (ttm)
- 53.4
- 52-week range
- $223.83–$438.27
- Off 52-week high
- 4.9%
- RSI (14)
- 96
- Volume vs avg
- 3.10×
- Score today
- 6.3/10